- Scrip Originals
- Featured Topics
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Osel, Inc.
Depending on financing, the company could start a Phase III trial of CBM588 as early as this year, but it’s looking to develop the microbiome therapeutic for a potentially broad array of cancers.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.